Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) Shares Outstanding (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Shares Outstanding data on record, last reported at $135.9 million in Q4 2025.

  • For Q4 2025, Shares Outstanding rose 26.19% year-over-year to $135.9 million; the TTM value through Dec 2025 reached $135.9 million, up 26.19%, while the annual FY2025 figure was $135.9 million, 26.19% up from the prior year.
  • Shares Outstanding reached $135.9 million in Q4 2025 per TNGX's latest filing, up from $111.6 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $135.9 million in Q4 2025 and bottomed at $48.4 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $95.0 million, with a median of $95.2 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding: skyrocketed 116.98% in 2021, then increased 0.53% in 2023.
  • A 5-year view of Shares Outstanding shows it stood at $87.6 million in 2021, then rose by 0.66% to $88.2 million in 2022, then increased by 15.9% to $102.2 million in 2023, then increased by 5.41% to $107.7 million in 2024, then rose by 26.19% to $135.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were $135.9 million in Q4 2025, $111.6 million in Q3 2025, and $110.9 million in Q2 2025.